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Background: Infection by nontuberculous mycobacteria (NTM) in patients with cystic ﬁbrosis (CF) is often associated with signiﬁcant morbidity.
Limited, conﬂicting results are published regarding risk factors for pulmonary NTM disease. We analysed factors potentially associated with NTM
in a large population of European patients with CF.
Methods: We investigated associations between presence of NTM and various factors for patients registered in the European Cystic Fibrosis
Society Patient Registry.
Results: 374 (2.75%) of 13,593 patients studied had at least one positive NTM culture within the study year. Age- and FEV1-adjusted odds of NTM
infection was more than 2.5 times higher (95%CI: 1.79; 3.60) in patients infected by Stenotrophomonas maltophilia than in patients not infected
(p b 0.0001), 2.36 times higher (95%CI: 1.80;3.08) in patients with ABPA than without (p b 0.0001), 1.79 times higher (95%CI: 1.34; 2.38) in
patients who use bronchodilators than in patients who don't (p b 0.0001), 1.49 times higher (95%CI: 1.18; 1.89) in patients who use inhaled
antibiotics than in patients who don't (p = 0.001), and 1.30 times higher (95%CI: 1.02; 1.66) in patients who use rhDNase than in patients who
don't (p = 0.032).
Conclusions: NTM-positive cultures in individuals with CF are associated with distinct clinical variables. Improved data collection identifying risk
factors for NTM infection will allow more focused screening strategies, and inﬂuence therapeutic choices and infection control measures in high-
risk patients.
© 2016 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords: Nontuberculous mycobacteria; Cystic ﬁbrosis; Risk factors; Patient registry; Epidemiology1. Introduction
Nontuberculous mycobacteria (NTM) represent a significant
emerging threat in patients with CF. The limited studies examining
NTM in CF to date have shown conflicting results with anincreasing rate of infection with NTM shown in most (but not all)
studied cohorts [1–3]. We currently do not understand the factors
which may predispose to NTM infection in CF. Recently, a large
US registry-based study reported potential risk factors for NTM
using CFF data [4]. No such study has been undertaken in Europe.
Given the geographical variation in the prevalence of different
NTM species between the US and Europe, the growing threat of
NTM infection in both adult and paediatric CF patients, and the
potential for person-to-person transmission, we undertook a
population-based analysis of the factors associated with the
isolation of NTM in a large population of European patients withe CC BY-NC-ND
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(ECFSPR) data.
2. Methods
The ECFSPR data collection methods have been described
elsewhere in detail [5]. Briefly, the registry annually collects data
from national CF registries and individual CF centres in Europe
pertaining to individuals with CF and records information on the
following: demographics, diagnosis, genotype, lung function,
growth, complications, microbiology, transplant and therapy.
Further details regarding the definitions are outlined on the
ECFSPR webpages [https://www.ecfs.eu/projects/ecfs-patient-
registry/Variables-Definitions] and in the 2008–2009 ECFSPR
annual report, downloadable at https://www.ecfs.eu/files/webfm/
webfiles/File/ecfs_registry/ECFSPR_Report0809_v32012.pdf.
We extracted data from the patients registered in ECFSPR in
year 2009 (latest registry update at time of analysis). For the
purposes of this cross-sectional study, to avoid patient and
information selection bias, we selected data from countries that
self-reported a good coverage (~90%) of their national CF
population, and that had an acceptable level of missing
information on isolation of NTM (b5%).
Further details regarding the methods are outlined in the
Supplementary Material.
We used logistic regressions to investigate associations between
the presence of NTM and age, sex, genotype, FEV1, BMI, therapy,
occurrence of infections and complications. We adjusted the
estimates for the effect of country, to account for potentially
different NTM screening and testing procedures, potential
differences in provision of care, and data collection methods
(such as sampling practices and time of FEV1 measurements).
We built the final multivariable model, adding first the
covariates that showed stronger evidence of an association with
the presence of NTM at univariate analysis. We evaluated the
impact of additional covariates through the computation of
p-values and the observation of the change of the odds ratios of
the covariates already in the model. We retained in the final
model the covariates for which the p-value was b0.05.
3. Results
The prevalence of NTM reported by the ECFS Patient
Registry for the year 2009 from each European country is
shown in the Supplementary Material. We focused our analysis
on patient data from France, Sweden and UK, which had a
high coverage of their national CF population, an acceptable
proportion of missing values for NTM, and that reported more
than 2 cases of NTM during the study year. The main
demographic and clinical characteristics of the study partici-
pants are summarised in Table 1.
Compared to NTM-negative patients, we found that NTM-
positive patients were older, had lower BMI values, worse FEV1,
were more likely to be infected by Pseudomonas aeruginosa and
by Stenotrophomonas maltophilia, were more likely to have
experienced pneumothorax requiring chest drain, haemoptysis
and liver disease, were more likely to make use of inhaledhypertonic saline, inhaled antibiotics, inhaled bronchodilators,
oxygen therapy, inhaled rhDNase, macrolides, ursodeoxycholic
acid and pancreatic enzymes.
3.1. Univariate models
When we formally tested these differences between NTM-
positive and negative populations through logistic regression
analysis (Table 2, we found a statistically significant association
between presence of NTM and age (p b 0.0001). After adjusting
for the effect of age (which would act as a confounder), there was
evidence of an association between NTM and FEV1 (p b0.0001),
BMI (p = 0.0016), inhaled hypertonic saline (p = 0.0002),
inhaled antibiotics (p b 0.0001), inhaled bronchodilators (p b
0.0001), oxygen therapy (p = 0.0099), use of inhaled rhDNase
(p b 0.0001), use of macrolides (p b 0.0001), use of
ursodeoxycholic acid (p b 0.0001), use of pancreatic enzymes
(p = 0.0033), P. aeruginosa colonisation (p = 0.0218), S.
maltophilia (p b 0.0001), ABPA (p b 0.0001), liver disease
(p = 0.0001), and haemoptysis (p = 0.0124).
3.2. Multivariable models
The following covariates were included in the final model,
built on 9382 patients, 323 of whom had NTM: age, FEV1,
infection with S. maltophilia, presence of ABPA, use of
bronchodilators, use of antibiotics and use of rhDnase.
As shown in Table 3, the odds of NTM infection was more than
2.5 times higher (95%CI: 1.79; 3.60) in patients infected by
S. maltophilia than in patients not infected (p b 0.0001), 2.36 times
higher (95%CI: 1.80; 3.08) in patients with ABPA than without
(p b 0.0001), 1.79 times higher (95%CI: 1.34; 2.38) in patients
who use bronchodilators than in patients who don't (p b 0.0001),
1.49 times higher (95%CI: 1.18; 1.89) in patients who use
inhaled antibiotics than in patients who don't (p = 0.001), and 1.30
times higher (95%CI: 1.02; 1.66) in patients who use rhDNase
than in patients who don't (p =0.032). For each additional 10 years
of age we estimate an increase of odds of infection of NTM by
17.5% (95%CI: 6.1; 30.2%, p = 0.002) and for each 10 percentage
point increase in predicted FEV1 we estimate a decrease of odds
of infection of NTM by 7.5% (95%CI: 3.0; 13.6%).
4. Discussion
This study represents the largest epidemiological analysis of
NTM in individuals with CF from European countries for
which there was evidence of unbiased reporting of NTM
infection (France, Sweden and the UK) and has identified a
number of clinical variables associated with NTM infection.
There are, however, a number of important limitations of this
study: its cross-sectional nature prevents identification of causal
factors for NTM infection; the lack of species information
about cultured NTM (as with previous US data [6] prevents
sub-group analysis of MAC and MABSC infection, which are
thought to infect different groups [7] and have distinct clinical
outcomes [8]; a large number of European countries provided
incomplete ECFSPR data on NTM preventing a larger, more
Table 1
Descriptive statistics of demographic and clinical characteristics of population under study, by NTM group.
Group
Covariate NTM = yes NTM = no All
Number of patients (%) 374 (2.7) 13,219 (97.3) 13,593
Sex: N (%) females 159 (42.5) 6279 (47.5) 6438 (47.4)
Age (years)
Mean 24.7 19.0 19.2
Standard deviation 12.4 12.8 12.8
Median 21.8 17.4 17.6
Range 0.6–71.1 0.0–82.5 0.0–82.5
Adults (≥18 years): N (%) 264 (70.6) 6365 (48.2) 6629 (48.8)
Children (b18 years): N (%) 110 (29.4) 6854 (51.8) 6964 (51.2)
Genotype
Number of patients undergone DNA analysis (%) 361 (96.5) 12654 (95.7) 13015 (95.7)
N (%) F508del/F508del 189 (52.3) 6284 (49.7) 6473 (49.7)
N (%) F508del/other 131 (36.3) 4968 (39.3) 5099 (39.2)
N (%) other/other 41 (11.4) 1402 (11.0) 1443 (11.1)
N (%) class I,II, III/I, II, III 242 (67.0) 8307 (65.6) 8549 (65.7)
N (%) Class I,II, III/IV, V 12 (3.3) 638 (5.0) 650 (5.0)
N (%) Class IV, V/IV, V 0 (0.0) 20 (0.2) 20 (0.1)
N (%) class undetermined 107 (29.7) 3689 (29.2) 3796 (29.2)
BMI
Adults (≥18 years)
BMI available for N (%) 256 (97.0) 5890 (92.5) 6146 (92.7)
N (%) b16.0 Kg/m2 7 (2.7) 113 (1.9) 120 (2.0)
N (%) [16.0–17.0) Kg/m2 9 (3.5) 203 (3.4) 212 (3.4)
N (%) [17.0–18.5) Kg/m2 32 (12.5) 694 (11.8) 726 (11.8)
N (%) [18.5–25.0) Kg/m2 174 (68.0) 4039 (68.6) 4213 (68.6)
N (%) [25.0–30.0) Kg/m2 26 (10.2) 683 (11.6) 709 (11.5)
N (%) ≥ 30.0 Kg/m2 8 (3.1) 158 (2.7) 166 (2.7)
Children (b18 years)
BMI available for N (%) 101 (91.8) 5686 (82.6) 5787 (83.1)
N (%) b −2 SDS 2 (2.0) 75 (1.3) 77 (1.3)
N (%) −2; +2 SDS 99 (98.0) 5608 (98.6) 5707 (98.6)
N (%) N +2 SDS 0 (0.0) 3 (0.1) 3 (0.1)
FEV1% of predicted
N (%) patients ≥6 years 359 (96.0) 10971 (83.0) 11330 (83.4)
FEV1% available for N (%) 341 (95.0) 9627 (87.7) 9968 (88.0)
N (%) b40% of predicted 82 (24.0%) 1417 (14.7%) 1499 (15.0%)
N (%) 40–80% of predicted 183 (53.7%) 4342 (45.1%) 4525 (45.4%)
N (%) N80% of predicted 76 (22.3%) 3868 (40.2%) 3944 (39.6%)
6–9 years: mean (SD) 65.8 (20.9) 89.5 (17.5) 89.4 (17.6)
10–14 years: mean (SD) 74.7 (22.6) 85.8 (19.3) 85.6 (19.4)
15–19 years: mean (SD) 63.0 (20.2) 73.3 (23.0) 72.8 (23.0)
20–24 years: mean (SD) 60.0 (24.2) 63.5 (24.2) 63.4 (24.2)
25–29 years: mean (SD) 56.3 (25.1) 58.8 (24.0) 58.7 (24.0)
30–34 years: mean (SD) 54.8 (17.7) 59.9 (24.2) 59.8 (24.1)
35–39 years: mean (SD) 53.8 (22.5) 58.7 (24.5) 58.5 (24.4)
40–44 years: mean (SD) 53.0 (26.9) 59.6 (26.3) 59.4 (26.3)
45+ years: mean (SD) 52.7 (24.0) 57.8 (24.7) 57.5 (24.7)
Infections: number of patients (%) with chronic infection by
Pseudomonas aeruginosa 155 (41.4) 3859 (29.2) 4014 (29.5)
Stenotrophomonas maltophilia 54 (14.4) 570 (4.3) 624 (4.6)
Burkholderia cepacia complex 7 (1.9) 292 (2.2) 299 (2.2)
Complications: number of patients (%) with
ABPA 96 (25.7) 1264 (9.6) 1360 (10.0)
Liver disease 61 (16.3) 1279 (9.7) 1340 (9.8)
Haemoptysis 21 (5.6) 343 (2.6) 364 (2.7)
Pneumothorax requiring chest drain 5 (1.3) 108 (0.8) 113 (0.8)
Malignancy 0 (0.0) 34 (0.3) 34 (0.3)
Therapy: number of patients (%) using
Insulin 61 (16.3) 1697 (12.8) 1758 (12.9)
Inhaled hypertonic saline 45 (12.0) 832 (6.3) 877 (6.4)
Inhaled antibiotic 191 (51.1) 4458 (33.7) 4649 (34.2)
(continued on next page)
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Table 1 (continued)
Group
Covariate NTM = yes NTM = no All
Inhaled bronchodilators 277 (74.1) 6676 (50.5) 6953 (51.2)
Oxygen therapy 40 (10.7) 739 (5.6) 779 (5.7)
Inhaled rhDNase 216 (57.7) 5165 (39.1) 5381 (39.6)
Macrolides 198 (52.9) 4971 (37.6) 5169 (38.0)
Ursodeoxycholic acid 121 (32.3) 3123 (23.6) 3244 (23.9)
Pancreatic enzymes 320 (85.6) 10818 (81.8) 11138 (81.9)
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infection; and finally the ECFSPR fails to capture the number
of samples sent for NTM culture (as well as for the other
infections) and therefore preventing an evaluation of the sampled
cohort and hence analysis of the true prevalence of NTM in
individuals with CF. Furthermore, not all the European countries
followed the ECFSPR guidelines relating to the definition of
chronic infections and the timing of FEV1 measurement.
However, the impact of the choice of any specific value from a
set of values over a year has been shown to be small [9]. To
overcome the problem differences artificially induced by the
study design (screening and reporting of NTM infections, data
collection practices, etc.)we adjusted our estimates by introducing
the country as a factor in the models.
Isolation of S. maltophilia was associated with the presence
of NTM, echoing a recent US CFF registry-based study [4],
potentially due to the fact that both are resistant bacteria thatTable 2
Results from univariate logistic regressions: effect of single covariates on the odds
Covariate
Sex (male vs female)
Age on 31/12/2009 or age at death if died during study year (years)
F508del genotype
F508del heterozygote vs F508del homozygote
No F508del allele vs F508del homozygote
Mutation class
class I,II,III/I,II,III vs class undetermined
class I,II,III/IV, V vs class undetermined
class IV,V/IV,V vs class undetermined
FEV1% of predicted
a
BMI z-score a
Use of inhaled hypertonic saline during study year a (Yes vs no)
Use of inhaled antibiotic during study year a (Yes vs no)
Use of inhaled bronchodilators during study year a (Yes vs no)
Use of Oxygen therapy during study year a (Yes vs no)
Use of rhDNase during study year a (Yes vs no)
Use of macrolide during study year a (Yes vs no)
Use of ursodeoxycholic acid during study year a (Yes vs no)
Use of pancreatic enzymes during study year a (Yes vs no)
Chronic infection by Pseudomonas aeruginosa a (Yes vs no)
Chronic infection by Staphylococcus aureus a (Yes vs no)
Chronic infection by Burkholderia cepacia complex a (Yes vs no)
Infection by Stenotrophomonas maltophilia a (Yes vs no)
Presence of ABPA during study year a (Yes vs no)
Daily use of insulin during study year a (Yes vs no)
Occurrence of Pneumothorax requiring chest drain during study year a (Yes vs no)
Presence of liver disease during study year a (Yes vs no)
Occurrence of haemoptysis major over 250 ml during study year a (Yes vs no)
Occurrence of malignancy during study year a (Yes vs no)
a Effect adjusted by age: age was included as additional covariate in the model.may thrive under conditions of high antibiotic usage. We also
observed a negative association of NTM with chronic P.
aeruginosa infection, similar to a recent US study [4].
The relationship between NTM-positive cultures and
macrolide use is unclear in our data. Univariate analysis suggested
a potential association between NTM-positive cultures and
macrolide use in keeping with a previous small, single-centre
study [10] suggesting that chronic azithromycin use might
predispose to MABSC infection by blocking autophagic
intracellular killing. However, multivariate analysis of our data
failed to demonstrate an association between NTM-positive
cultures and macrolide use. Recent data from a US population-
based study [4] and a small case–control study from France [7]
suggest that the use of maintenance macrolide therapy may be
associated with a decreased likelihood of NTM. Given the
multi-collinearity of macrolide usage and chronic pseudomonas
infection in our dataset, we are unable to estimate the effect ofof being infected by NTM.
OR 95%CI p-Value
1.223 0.994; 1.506 0.057
1.030 1.023; 1.038 b0.0001
0.515
0.877 0.699; 1.099
0.972 0.690; 1.370
0.540
1.009 0.807; 1.262
0.652 0.358; 1.187
b0.001 b0.001; N999.999
0.986 0.981; 0.990 b0.0001
0.872 0.800; 0.949 0.002
1.825 1.323; 2.518 0.0002
1.934 1.568; 2.386 b0.0001
2.484 1.962; 3.146 b0.0001
1.570 1.114; 2.211 0.010
2.072 1.682; 2.553 b0.0001
1.542 1.248; 1.906 b0.0001
1.595 1.273; 1.997 b0.0001
1.652 1.182; 2.309 0.003
1.299 1.039; 1.624 0.022
1.153 0.820; 1.620 0.412
0.702 0.329; 1.498 0.360
3.576 2.640; 4.843 b0.0001
3.118 2.453; 3.965 b0.0001
0.973 0.731; 1.295 0.850
1.418 0.574; 3.501 0.449
1.741 1.314; 2.305 0.0001
1.793 1.135; 2.833 0.012
b0.001 b0.001; N999.999 0.973
Table 3
Results from multivariable logistic regressions: effect on odds of NTM infection
of age, FEV1, infection with Stenotrophomonas maltophilia, presence of
ABPA, use of bronchodilators, use of antibiotics, and use of rhDnase. The
estimates are adjusted by the effect of country. The model was built using data
from 9382 CF patients.
Covariate Odds
ratio
95% CI p-Value
Stenotrophomonas maltophilia (Yes vs no) 2.54 1.79 3.60 b0.0001
ABPA this year (Yes vs no) 2.36 1.80 3.08 b0.0001
Inhaled bronchodilators this year (Yes vs no) 1.79 1.34 2.38 b0.0001
Inhaled antibiotic this year (Yes vs no) 1.49 1.18 1.89 0.001
Use of rhDNase this year (Yes vs no) 1.30 1.02 1.66 0.032
Age (decade) 1.17 1.06 1.30 0.002
FEV1% of predicted, unit expressed as change
of 10 percent points.
0.93 0.88 0.97 0.003
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treatment of these variables in the regressionmodel is contained in
the Supplementary Material. Large, longitudinal studies will be
required to definitively determine whether macrolides may
predispose to NTM infection in individuals with CF.
We also found an association between ABPA and NTM-
positive cultures which has been reported by some [11] but not
other studies [7,10,12]; inconsistencies potentially due to differ-
ences in case definitions for ABPA and/or variations in oral steroid
usage. While there are a number of plausible reasons for a causal
relationship between ABPA and NTM (including
ABPA-associated immunomodulation [10,13,14] and/or reduced
airway clearance), our data highlights the importance of heightened
vigilance for NTM infection in CF patients with ABPA.
Our study shows a relationship between the use of inhaled
bronchodilators, inhaled antibiotics and, to a lesser extent, inhaled
rhDNAse with NTM isolation in patients with CF. It has been
suggested [15,16] that rhDNAase may promote infection
with MABSC by providing degraded DNA as a mycobacterial
nutrient. Use of inhaled corticosteroids has been associated with
an increased risk of pulmonary NTM disease in patients with
COPD [17] and asthma [18]. Previous studies in CF populations
to date have not demonstrated a similar effect [7,19].
In summary, our study identifies a number of potential risk
factors for the acquisition of NTM in CF that will require further
study. Understanding these risk factors is key to reducing the
incidence of NTM infection and will allow a more focused
screening strategy for NTM, and could influence therapeutic
choices and infection control measures in these high-risk patients.
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